| Ident. | Authors (with country if any) | Title |
|---|
| 001212 |
Constance Hammond [France] ; Rachida Amman [France] ; Bernard Bioulac [France] ; Liliana Garcia [France] | Latest View on the Mechanism of Action of Deep Brain Stimulation |
| 002450 |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease |
| 002497 |
Ruediger Hilker [Allemagne] ; Juergen Voges [Allemagne] ; Mehran Ghaemi [Allemagne] ; Ralf Lehrke [Allemagne] ; Jobst Rudolf [Allemagne] ; Athanasios Koulousakis [Allemagne] ; Karl Herholz [Allemagne] ; Klaus Wienhard [Allemagne] ; Volker Sturm [Allemagne] ; Wolf-Dieter Heiss [Allemagne] | Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in Parkinsonian humans |
| 002519 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 002556 |
Ergun Y. Uc [États-Unis] ; Gerald A. Dienel [États-Unis] ; Nancy F. Cruz [États-Unis] ; Sami I. Harik [États-Unis] | β-Adrenergics enhance brain extraction of levodopa |
| 002694 |
Jonathan O. Dostrovsky [Canada] ; Andres M. Lozano [Canada] | Mechanisms of deep brain stimulation |
| 002695 |
Alim-Louis Benabid [France] ; Abdelhamid Benazzous [France] ; Pierre Pollak [France] | Mechanisms of deep brain stimulation |
| 002696 |
Jerrold L. Vitek [États-Unis] | Mechanisms of deep brain stimulation: Excitation or inhibition |
| 002911 |
Oum-Kaltoum Hassani [France] ; Mireille Mouroux [France] ; Georg Andrees Bohme [France] ; Jean-Marie Stutzmann [France] ; Jean Feger [France] | Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain |
| 002931 |
Jon H. Falkenberg [États-Unis] ; Paul A. Laizzo [États-Unis] ; Linda K. Mcloon [États-Unis] | Physiological assessment of muscle strength in vitro after direct injection of Doxorubicin into rabbit sternocleidomastoid muscle |
| 002952 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
| 002966 |
Fabrizio Stocchi [Italie] ; Laura Vacca [Italie] ; Alfredo Berardelli [Italie] ; Francesca De Pandis [Italie] ; Stefano Ruggieri [Italie] | Long-duration effect and the postsynaptic compartment : Study using a dopamine agonist with a short half-life |
| 002A17 |
Y. R. Wu [Taïwan] ; R. Levy [Canada] ; P. Ashby [Canada] ; R. R. Tasker [Canada] ; J. O. Dostrovsky [Canada] | Does stimulation of the GPi control dyskinesia by activating inhibitory axons? |
| 002A36 |
Krishna P. Datla [Royaume-Uni] ; Stavia B. Blunt [Royaume-Uni] ; David T. Dexter [Royaume-Uni] | Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions |
| 002A76 |
| Abstracts from International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Orlando, FL, USA, November 16-18, 1999 |
| 002A96 |
Hasmet A. Hanagasi [Turquie] ; Gülüstü Kaptanoglu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa |
| 002B46 |
Pieter Joost Van Wattum [États-Unis] ; Phillip B. Chappell [États-Unis] ; Daniel Zelterman [États-Unis] ; Lawrence D. Scahill [États-Unis] ; James F. Leckman [États-Unis] | Patterns of response to acute naloxone infusion in Tourette's syndrome |
| 002C10 |
Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Endogenous dopaminergic tone and dopamine agonist action |
| 002D09 |
S. Spieker [Allemagne] ; P.-A. Löschmann [Allemagne] ; T. Klockgether [Allemagne] | The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations |
| 002D87 |
D. Kunz [Allemagne] ; F. Bes [Allemagne] | Melatonin as a therapy in REM sleep behavior disorder patients : An open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation |
| 002E11 |
M. Merello [Argentine] ; Andrew Lees (neurologue) [Royaume-Uni] ; J. Balej [Argentine] ; A. Cammarota [Argentine] ; R. Leiguarda [Argentine] | GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine |
| 002E25 |
R. B. Innis [États-Unis] ; K. L. Marek [États-Unis] ; K. Sheff [États-Unis] ; S. Zoghbi [États-Unis] ; J. Castronuovo [États-Unis] ; A. Feigin [États-Unis] ; J. P. Seibyl [États-Unis] | Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT |
| 002E66 |
M. Merello [Argentine] ; J. Balej [Argentine] ; M. Delfino [Argentine] ; A. Cammarota [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine] | Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease |
| 002E73 |
R. Ceravolo [Italie] ; S. Salvetti [Italie] ; P. Piccini [Royaume-Uni] ; C. Lucetti [Italie] ; G. Gambaccini [Italie] ; U. Bonuccelli [Italie] | Acute and chronic effects of clozapine in essential tremor |
| 002E96 |
F. Ovsiew [États-Unis] ; K. J. Meador [États-Unis] ; K. Sethi [États-Unis] | Verapamil for severe hyperkinetic movement disorders |
| 002F51 |
P. G. Wasielewski [États-Unis] ; J. M. Burns [États-Unis] ; W. C. Koller [États-Unis] | Pharmacologic treatment of tremor |
| 002F79 |
S. Przedborski [États-Unis] ; V. Jackson-Lewis [États-Unis] | Mechanisms of MPTP toxicity |
| 002F86 |
N. R. Hughes [Royaume-Uni] ; A. T. Mcknight [Royaume-Uni] ; G. N. Woodruff [Royaume-Uni] ; M. P. Hill [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism |
| 003080 |
M. Gassen [Allemagne] ; A. Gross [Israël] ; M. B. H. Youdim [Israël] | Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine |
| 003198 |
G. Dziewczapolski [Argentine] ; L. B. Menalled [Argentine] ; M. T. Savino [Argentine] ; M. Mora [Argentine] ; F. J. E. Stefano [Argentine] ; O. Gershanik [Argentine] | Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the "super-off" phenomenon |
| 003546 |
| |
| 003683 |
W. G. Tatton [Canada] | Selegiline can mediate neuronal rescue rather than neuronal protection |
| 003A74 |
W. Koller ; G. Herbster ; J. Gordon | PHNO, a novel dopamine agonist, in animal models of parkinsonism |
